S
ZNTL icon

SignatureFD’s Zentalis Pharmaceuticals ZNTL Stock Holding History

SignatureFD’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-47
Closed -$741 – 3272
2024
Q1 		$741 Buy
47
+17
+57% +$234 ﹤0.01% 2985
2023
Q4 		$455 Sell
30
-21
-41% -$306 ﹤0.01% 2985
2023
Q3 		$1.02K Sell
51
-12
-19% -$305 ﹤0.01% 2936
2023
Q2 		$1.78K Sell
63
-12
-16% -$288 ﹤0.01% 2844
2023
Q1 		$1.29K Hold
75
– – ﹤0.01% 2926
2022
Q4 		$1.51K Sell
75
-10
-12% -$215 ﹤0.01% 2882
2022
Q3 		$2K Hold
85
– – ﹤0.01% 2866
2022
Q2 		$2K Buy
+85
New +$2.25K ﹤0.01% 2822
2022
Q1 		– Sell
-25
Closed -$2K – 3351
2021
Q4 		$2K Buy
+25
New +$1.93K ﹤0.01% 2814
2021
Q3 		– Sell
-16
Closed -$1K – 3238
2021
Q2 		$1K Buy
+16
New +$857 ﹤0.01% 2866

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SignatureFD's ZNTL Position: Q2 2024 in Review

SignatureFD sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2024, closing a stake of 47 shares — an estimated $741 sold.

SignatureFD first reported a position in ZNTL in Q2 2021 and held it in 10 quarters. The position peaked at $2K in Q3 2022. 145 funds tracked by Wall St. Rank hold ZNTL as of Q2 2024.

  • SignatureFD reported no remaining Zentalis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • SignatureFD sold 47 Zentalis Pharmaceuticals shares in Q2 2024, an estimated $741.
  • SignatureFD first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 10 quarters.
  • SignatureFD's Zentalis Pharmaceuticals position peaked at $2K in Q3 2022.
  • 145 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2024.

Based on SignatureFD's 13F filing for Q2 2024, filed 29 Jul 2024.